NEPAFENAC 0.1%w/v IP

A topical ocular NSAID for the treatment of pain and inflammation after cataract surgery. (Richard Lindstrom, 2006) A safe and effective agent in maintaining mydriasis during cataract surgery. (Fernando Roberte Zanetti, 2012) Displays better efficacy than conventional NSAIDs in patients' tolerability and ocular inflammation associated with cataract surgery. (Xinyu Zhao, 2017) More effective than Ketorolac in reducing the incidence of postoperative conjunctival hyperemia and ocular discomfort. (Xinyu Zhao, 2017) Shows superiority to Ketorolac in patients' tolerability following cataract surgery. (Xinyu Zhao, 2017) Offers a better visual ability and maintains intraoperative mydriasis during cataract surgery. (Xinyu Zhao, 2017) A promising drug for the treatment of posterior segment inflammation, including cystoid macular edema. (Seenu M Hariprasad, 2007) An effective and safe therapy for treating chronic cystoid macular edema in patients who are steroid responders. (Keith A Warren, 2008) More effective than fluorometholone in preventing cystoid macular edema and blood-aqueous barrier disruption after cataract surgery. (Kensaku Miyake, 2011)